356 related articles for article (PubMed ID: 31879772)
1. Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids.
Pinilla-Redondo R; Mayo-Muñoz D; Russel J; Garrett RA; Randau L; Sørensen SJ; Shah SA
Nucleic Acids Res; 2020 Feb; 48(4):2000-2012. PubMed ID: 31879772
[TBL] [Abstract][Full Text] [Related]
2. Viral diversity threshold for adaptive immunity in prokaryotes.
Weinberger AD; Wolf YI; Lobkovsky AE; Gilmore MS; Koonin EV
mBio; 2012 Dec; 3(6):e00456-12. PubMed ID: 23221803
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas systems are widespread accessory elements across bacterial and archaeal plasmids.
Pinilla-Redondo R; Russel J; Mayo-Muñoz D; Shah SA; Garrett RA; Nesme J; Madsen JS; Fineran PC; Sørensen SJ
Nucleic Acids Res; 2022 May; 50(8):4315-4328. PubMed ID: 34606604
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas: evolution of an RNA-based adaptive immunity system in prokaryotes.
Koonin EV; Makarova KS
RNA Biol; 2013 May; 10(5):679-86. PubMed ID: 23439366
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas: Complex Functional Networks and Multiple Roles beyond Adaptive Immunity.
Faure G; Makarova KS; Koonin EV
J Mol Biol; 2019 Jan; 431(1):3-20. PubMed ID: 30193985
[TBL] [Abstract][Full Text] [Related]
6. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
Hidalgo-Cantabrana C; Goh YJ; Barrangou R
J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
[TBL] [Abstract][Full Text] [Related]
7. A Type IV-A CRISPR-Cas System in
Crowley VM; Catching A; Taylor HN; Borges AL; Metcalf J; Bondy-Denomy J; Jackson RN
CRISPR J; 2019 Dec; 2(6):434-440. PubMed ID: 31809194
[TBL] [Abstract][Full Text] [Related]
8. Adaptation in CRISPR-Cas Systems.
Sternberg SH; Richter H; Charpentier E; Qimron U
Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas systems: beyond adaptive immunity.
Westra ER; Buckling A; Fineran PC
Nat Rev Microbiol; 2014 May; 12(5):317-26. PubMed ID: 24704746
[TBL] [Abstract][Full Text] [Related]
10. Unravelling the structural and mechanistic basis of CRISPR-Cas systems.
van der Oost J; Westra ER; Jackson RN; Wiedenheft B
Nat Rev Microbiol; 2014 Jul; 12(7):479-92. PubMed ID: 24909109
[TBL] [Abstract][Full Text] [Related]
11. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections.
Gholizadeh P; Aghazadeh M; Asgharzadeh M; Kafil HS
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2043-2051. PubMed ID: 28601970
[TBL] [Abstract][Full Text] [Related]
12. Type IV-A3 CRISPR-Cas systems drive inter-plasmid conflicts by acquiring spacers in trans.
Benz F; Camara-Wilpert S; Russel J; Wandera KG; Čepaitė R; Ares-Arroyo M; Gomes-Filho JV; Englert F; Kuehn JA; Gloor S; Mestre MR; Cuénod A; Aguilà-Sans M; Maccario L; Egli A; Randau L; Pausch P; Rocha EPC; Beisel CL; Madsen JS; Bikard D; Hall AR; Sørensen SJ; Pinilla-Redondo R
Cell Host Microbe; 2024 Jun; 32(6):875-886.e9. PubMed ID: 38754416
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of CRISPR-Cas Type III prokaryotic defence systems.
Molina R; Sofos N; Montoya G
Curr Opin Struct Biol; 2020 Dec; 65():119-129. PubMed ID: 32712502
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas systems in oral microbiome: From immune defense to physiological regulation.
Gong T; Zeng J; Tang B; Zhou X; Li Y
Mol Oral Microbiol; 2020 Apr; 35(2):41-48. PubMed ID: 31995666
[TBL] [Abstract][Full Text] [Related]
15. Mobile Genetic Elements and Evolution of CRISPR-Cas Systems: All the Way There and Back.
Koonin EV; Makarova KS
Genome Biol Evol; 2017 Oct; 9(10):2812-2825. PubMed ID: 28985291
[TBL] [Abstract][Full Text] [Related]
16. Characterization and applications of Type I CRISPR-Cas systems.
Hidalgo-Cantabrana C; Barrangou R
Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
[TBL] [Abstract][Full Text] [Related]
17. Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum.
Özcan A; Pausch P; Linden A; Wulf A; Schühle K; Heider J; Urlaub H; Heimerl T; Bange G; Randau L
Nat Microbiol; 2019 Jan; 4(1):89-96. PubMed ID: 30397343
[TBL] [Abstract][Full Text] [Related]
18. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
[TBL] [Abstract][Full Text] [Related]
19. Exploiting CRISPR/Cas: interference mechanisms and applications.
Richter H; Randau L; Plagens A
Int J Mol Sci; 2013 Jul; 14(7):14518-31. PubMed ID: 23857052
[TBL] [Abstract][Full Text] [Related]
20. Diversity of CRISPR/Cas system in Clostridium perfringens.
Long J; Xu Y; Ou L; Yang H; Xi Y; Chen S; Duan G
Mol Genet Genomics; 2019 Oct; 294(5):1263-1275. PubMed ID: 31134321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
